Factors regulating microglia activation by Katrin Kierdorf & Marco Prinz
“fncel-07-00044” — 2013/4/22 — 12:53 — page 1 — #1
REVIEW ARTICLE
published: 23 April 2013
doi: 10.3389/fncel.2013.00044
Factors regulating microglia activation
Katrin Kierdorf 1,2 and Marco Prinz1,3*
1 Institute of Neuropathology, University of Freiburg, Freiburg, Germany
2 Faculty of Biology, University of Freiburg, Freiburg, Germany
3 BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany
Edited by:
Amanda Sierra, Ikerbasque
Foundation, University of the Basque
Country, Spain
Reviewed by:
Colm Cunningham, Trinity College of
Dublin, Ireland
William E. Seaman, University of
California at San Francisco, USA
*Correspondence:
Marco Prinz, Institute of
Neuropathology, University of
Freiburg, Breisacher Str. 64, D-79106
Freiburg, Germany.
e-mail: marco.prinz@uniklinik-
freiburg.de
Microglia are resident macrophages of the central nervous system (CNS) that display high
functional similarities to other tissue macrophages. However, it is especially important
to create and maintain an intact tissue homeostasis to support the neuronal cells, which
are very sensitive even to minor changes in their environment. The transition from the
“resting” but surveying microglial phenotype to an activated stage is tightly regulated by
several intrinsic (e.g., Runx-1, Irf8, and Pu.1) and extrinsic factors (e.g., CD200, CX3CR1,
andTREM2). Under physiological conditions, minor changes of those factors are sufﬁcient
to cause fatal dysregulation of microglial cell homeostasis and result in severe CNS
pathologies. In this review, we discuss recent achievements that gave new insights into
mechanisms that ensure microglia quiescence.
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MICROGLIA – GATEKEEPER OF TISSUE HOMEOSTASIS IN
THE CNS
Tissuemacrophages are found in virtually all organs of the body. In
the central nervous system (CNS), specialized tissue macrophages
were ﬁrst identiﬁed within the “third element,” or “mesoglia,”
by Pio del Rio-Hortega (1882–1945). He ﬁrst characterized a
small cell in the neuroectodermal tissue, which apparently was
of mesodermal origin and seemed to be related to other tissue
macrophages in the body (del Rio-Hortega, 1919, 1932). The
specialized tissue macrophage of the CNS is known today as
microglia.
The postulated mesodermal origin of microglia by Pio del Rio-
Hortega was under investigation for several decades. However,
the issue about the exact origin of microglia was not solved. An
increasing number of studies pointed to a very early colonization
of the CNS by mesodermal progenitors (Kaur et al., 2001) and
indicated thatmicroglial progenitors arise from the yolk sac (Alliot
et al., 1999). More recently, we and others showed that microglia
are derived from the primitive hematopoiesis in the yolk sac and
excluded a contribution of deﬁnitive hematopoietic stem cells
(HSCs) to the generationof microglia (Ginhoux et al., 2010; Schulz
et al., 2012). It was further shown that microglia are derived from
an uncommitted F4/80-negative erythromyeloid precursor in the
yolk sac that develops via immature F4/80−CX3CR1− myeloid
progenitor subsets into F4/80+CX3CR1+ mature macrophages,
which ﬁnally colonize the CNS to give rise to microglia (Kierdorf
et al., 2013).
Upon infection or insults within the adult CNS parenchyma,
microglia are rapidly activated and efﬁciently phagocytose
pathogens and dying cells (Hanisch and Kettenmann, 2007; Ran-
sohoff and Perry, 2009). Furthermore, microglia release many
effector molecules for the recruitment of other immune cells
from the blood to limit infections in the CNS, or which serve as
antigen presenting cells of phagocytosed material (Saijo and Glass,
2011). In addition, they help in the regeneration of damaged tissue
by secretion of growth factors and anti-inﬂammatory molecules
(Saijo and Glass, 2011). Therefore, microglia are indispensable in
the adult CNS as stabilizers and modulators of tissue homeostasis
under physiological conditions.
Microglia are well integrated in the neuronal glial network of
the healthy CNS. They are distributed in all brain regions with
varying density between 5% in the corpus callosum and 12% in the
substantia nigra (Lawson et al., 1990). However, the reason for this
difference in cell frequency has not been resolved. The morphol-
ogy of a “resting” microglial cell is characterized by a very small
cell soma with elongated ramiﬁed processes (Cuadros and Navas-
cués, 1998). Under healthy conditions, microglial cell processes
do not overlap with processes of neighboring cells and each cell
seems to have a scavenger function for its own immediate area. The
position of the cell soma remains stable, whereas the processes of
the resting microglia are continuously elongating and retracting
to explore the tissue environment. In vivo imaging of microglia in
intact brain tissue demonstrated highly dynamic processes which
continuously scan the surrounding microenvironment (Nimmer-
jahn et al., 2005). Upon recognition of a pathogen or other
inﬂammatory stimuli,microglia can rapidly retract their processes
and become efﬁcient mobile effector cells (Davalos et al., 2005).
These observations highlighted the important immune surveil-
lant function of microglia in the healthy CNS parenchyma. In
general, microglia activation is triggered by a plethora of well
described subsets of immune receptors such as Toll-like recep-
tors (TLRs), scavenger receptors, and numerous cytokine and
chemokine receptors.
In this review, however, we focus on several distinct exoge-
nous as well as endogenous signals and factors that are important
for the maintenance of the “resting” state of microglia. First, we
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describe the interaction between microglia and their surrounding
cells, such as neurons, which have a major role in transmitting
survival and inhibitory signals to resting microglia. Next, we dis-
cuss endogenous microglial signals, mainly transcription factors,
which modulate the transcriptional program in these cells that
either lead to changes in microglial features or maintain their rest-
ing state. Small perturbations in one of these signaling cascades
can lead to a spontaneous activation of microglia without any
infection or injury to the CNS. However, this spontaneous acti-
vated phenotype may be harmful to the neuronal network via
induced major changes in the tissue environment, and result in
severe damage of the neuronal integrity and function.
EXOGENOUS SIGNALS FOR MICROGLIA ACTIVATION
In the non-diseased adult CNS, microglia communicate with
the surrounding glial cells as well as with neighboring neurons.
This communication is enabled by a versatile subset of different
cell surface molecules on the microglial cell membrane. Indeed,
most of the surface molecules of microglia belong to the families
of cytokine receptors, scavenger receptors, and pattern recogni-
tion receptors (PRRs), as well as to the chemokine receptors,
which recognize pro-inﬂammatory mediators upon inﬂamma-
tion or infection. Most of these receptors are binding ligands
that are secreted by, or expressed on the membrane of healthy
neurons. Activation of these receptor subsets by inﬂammatory
molecules or pathogens result in a rapid activation of the “resting”
microglia to a motile effector cell which contributes to the ongoing
inﬂammation. However, for a small heterogeneous subset of
molecules known as “inhibitory molecules” on the surface of
microglia, their ligand recognition and binding does not result
in a pro-inﬂammatory activation (Ransohoff and Perry, 2009).
Otherwise, the binding of these ligands is necessary for keeping up
the resting ramiﬁed phenotype of microglia in the healthy CNS
(Linnartz and Neumann, 2012).
The surface molecule CD200 is widely expressed not only
on neurons, but also on astrocytes and oligodendrocytes (Bar-
clay et al., 2002). Its receptor CD200R is exclusively expressed
on macrophages in the CNS, including microglia. The inter-
action of neuronal CD200 with CD200R leads to inactivation
of microglia and keeps them in a resting state (Hoek et al.,
2000; Biber et al., 2007) (Figure 1). Analysis of microglia of
CD200-deﬁcient mice revealed a less ramiﬁed morphology with
shorter processes and upregulation of CD45 (leukocyte common
antigen) and CD11b (complement receptor 3/integrin αmβ2),
which are also markers of activation (Hoek et al., 2000). Addi-
tionally, microglia in non-immunized CD200-deﬁcient animals
seemed to form aggregate-like structures, which are typically
only found in neurodegenerative disease with strong microglial
activation. Following facial nerve axotomy, a model for local
neuronal degeneration,CD200-deﬁcient neurons elicited an accel-
erated microglial response in the lesioned nucleus. In the animal
model for multiple sclerosis (MS), experimental autoimmune
encephalomyelitis (EAE), deﬁciency of CD200 resulted in a more
rapid onset of disease (Hoek et al., 2000). These ﬁndings indicate
that without the CD200–CD200R signaling, microglia develop an
activated phenotype in the CNS.
FIGURE 1 | Exogenous signals and their receptors on microglia. Microglia
are equipped with a group of surface receptors which trigger signals in
microglia under “resting” conditions. Many of these signals are ligands which
are released or expressed on the surface of neurons. Inhibitory receptors like
CX3CR1, CD200R, and CD172a/Sirp alpha have their ligands on the surface of
healthy neurons. A loss of the signal also indicates a loss of neuronal integrity.
Receptors such asTREM2 and purinergic receptors are essential to mimic
neuronal injury and induce phagocytotic and anti-inﬂammatory functions in
microglia. The crosstalk between microglia and neurons is also important for
the survival of microglia. Neurons release factors like IL-34 and Csf1 which
bind to Csf1r on the surface of microglia and induce cell survival or
proliferation.
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The G-protein-coupled seven-transmembrane chemokine
receptor, CX3CR1, is expressed on monocytes, macrophages, den-
dritic cells (DCs), as well as on natural killer (NK) cells. In the CNS
parenchyma, CX3CR1 expression is restricted to the macrophage
population, e.g., microglia (Jung et al., 2000). Its only known lig-
and, CX3CL1, is expressed on different neuronal subsets in the
adult CNS (Kimet al., 2011). Also called fractalkine or neurotactin,
CX3CL1 was ﬁrst described as a member of a new chemokine class
with a speciﬁc cysteine motif containing three amino acids sepa-
rating both cysteines in the chemokine domain (Bazan et al., 1997;
Pan et al., 1997). The ligand can be found in a secreted form as
well as in a membrane-bound variant (Hughes et al., 2002). Har-
rison et al. (1998) showed that the binding between of neuronal
CX3CL1 to the microglial CX3CR1 seems to play a fundamental
role in the interaction of neurons and microglia in the healthy and
diseased brain. Furthermore, they postulated in this study that
CX3CL1 binding to CX3CR1 is a fundamental signaling pair in
neurophysiology.
Cardona et al. (2006) also found high levels of secreted CX3CL1
in the CNS parenchyma under healthy conditions. They fur-
ther demonstrated that CX3CR1-deﬁcient microglia show an
over-activated phenotype in three different diseases models.
The loss of fractalkine signaling led to an enhanced neuronal
cell death in animal models for Parkinson’s disease and other
motor neuron disorders. The accelerated neurotoxicity of the
CX3CR1-deﬁcient microglia seemed to worsen neurodegenerative
diseases. Nevertheless, several studies on the role of CX3CR1-
deﬁciency in animal models for Alzheimer’s disease (AD) revealed
quite divergent results (Fuhrmann et al., 2010; Lee et al., 2010;
Liu et al., 2010; Prinz et al., 2011). In AD, CX3CR1 deﬁciency
appeared to be beneﬁcial by resulting in reduced neuronal loss
and improved behavioral deﬁcits. Altogether, these results indi-
cated that CX3CR1-deﬁciency has several effects on the course
and pathology of inﬂammatory or neurodegenerative CNS dis-
eases. Therefore, neuron–microglia communication via CX3CL1
and CX3CR1 could play different roles under inﬂammatory and
neurodegenerative CNS conditions (Prinz and Priller, 2010).
Notably, recent investigations showed a pivotal role for
the CX3CR1–CX3CL1 signaling under physiological conditions
(Figure 1). In the postnatal brain, the formation of mature neu-
ral circuits depends on the elimination of redundant synapses.
Little was known about the mechanisms of this process called
“synaptic pruning” (Hua and Smith, 2004). Recent investiga-
tions showed that the ligand CX3CL1 is highly expressed during
this time of synapse maturation (Paolicelli et al., 2011). The
authors could elegantly demonstrate that microglia are in direct
contact with these synapses and remove unwanted synapses by
phagocytosis. This study highlighted the non-redundant role of
CX3CR1 on microglia for this process. CX3CR1-deﬁcient ani-
mals showed a reduced number of microglia during the ﬁrst
weeks after birth (Paolicelli et al., 2011). However, during the
embryonic phase and in adult animals there was no alteration
in microglial cell numbers detected in these animals (Kier-
dorf et al., 2013). The authors pointed out that CX3CR1 is an
important regulator of microglial surveillance (Paolicelli et al.,
2011). Reduced microglial cell number in CX3CR1-deﬁcient ani-
mals resulted in the development of immature neuronal circuits.
In contrast, CX3CR1-deﬁcient animals revealed a high density
of spines and functional excitatory synapses, which are more
known to be related to a mature phenotype than delayed brain
development.
In addition, another study reported that CX3CR1-deﬁcient ani-
mals exhibited an inhibition in microglial recruitment to forming
synapses in the barrel ﬁeld of the somatosensory cortex, leading
to an abnormal synapse formation in this area (Hoshiko et al.,
2012). Therefore, interaction of neurons and microglia appears
to be essential for proper synapse formation in the postnatal
cortex.
Earlier publications did not indicate an essential role of
CX3CR1 in the healthy brain. Most studies were dealing with
the role of this receptor under inﬂammatory conditions (Jung
et al., 2000; Cardona et al., 2006). Recent investigations in healthy
CX3CR1-deﬁcient animals showed a harmful effect of this muta-
tion for adult neurogenesis and hippocampal circuit integrity. The
number of neuronal precursors in the hippocampus was massively
decreased and led to diminished adult neurogenesis (Bachstet-
ter et al., 2011). Reintroducing CX3CL1 in the hippocampus of
aged animals could rescue of the decreasing neurogenesis generally
observed in aging animals. Furthermore, a reduction of CX3CR1
in adult animals resulted in adecrease inneurogenesis. The authors
showed that a lower level of neurogenesis is mediated by highly
elevated levels of hippocampal pro-inﬂammatory cytokines such
as interleukin (IL)-1β, which is secreted by microglia, and is
toxic to the developing neuronal progenitors. This supports the
role of CX3CR1 signaling in keeping microglia in a quiescent
state.
Another study further evaluated this theory and found that
CX3CR1-deﬁcient animals display cognitive impairment (Rogers
et al., 2011). They established performance deﬁcits in fear condi-
tioning as well as in the Morris water maze, which is associated
with learning, in CX3CR1-deﬁcient mice. Mice lacking this recep-
tor had signiﬁcant impairment in long-termpotentiation, which is
widely considered to underlie learning and memory. The authors
demonstrated an essential role of IL-1β in theseCX3CR1-mediated
impairments by reversing the deﬁcits of CX3CR1-deﬁciency via
application of IL-1R antagonists.
There are many other inhibitory surface receptors or molecules
on the surface of microglia which are mostly interacting with lig-
ands secreted or expressed on the surface of neurons, such as
CD47. CD47 is expressed ubiquitously, including on neurons,
transmits a“do not eatme”signal to themicroglia via CD172a/Sirp
alpha (van Beek et al., 2005; Biber et al., 2007) (Figure 1). Another
glycoprotein identiﬁed on microglia is known as the triggering
receptor expressed on myeloid cells 2 (TREM2), which was linked
to an anti-inﬂammatory phenotype (Colonna, 2003). TREM2
is associated with the adaptor protein DNAX-activating pro-
tein of 12-kDa (DAP12), which transmits the signal from the
receptor to the intracellular signaling cascade. TREM2 is essen-
tial for phagocytosis of, for example, apoptotic cell membranes
by microglia (Neumann and Takahashi, 2007). Furthermore,
TREM2 was shown to have beneﬁcial effects in autoimmune CNS
demyelination (Takahashi et al., 2007). Here, myeloid precursors
from bone marrow cultures, which were lentivirally transduced
to overexpress TREM2, were transplanted into EAE animals.
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The resultant disease amelioration in this animal model for MS
indicated that TREM2 may be the key receptor that triggers tis-
sue repair and limits CNS damage. Mutations in TREM2 or
DAP12 are associated with a severe neurodegenerative disease
known as polycystic lipomembranous osteodysplasia with scleros-
ing leukoencephalopathy (PLOSL), which is further characterized
by a form of early onset dementia and formation of bone cysts
(Paloneva et al., 2001; Klünemann et al., 2005).
Microglia also express receptors that trigger essential cellular
survival and developmental signals. One of the receptors which
plays a major role in microglial development and survival is the
receptor for colony stimulating factor 1 (Csfr1), which is also
known to regulate the differentiation and survival of peripheral
macrophages (Chitu and Stanley, 2006) (Figure 1). Csf1r binds
Csf1,which is important for themaintenance of manymacrophage
subsets (Cecchini et al., 1994). Csf1r-deﬁcient animals show deﬁ-
ciency in several subsets of mononuclear phagocytes andmicroglia
are completely absent in thesemice (Dai et al., 2002; Ginhoux et al.,
2010). Ginhoux et al. (2010) further showed that the development
of microglia and primitive yolk sac macrophages is completely
dependent on Csf1r signaling. However, the Csf1op/op mouse
strain with a natural occurring null mutation in Csf1 did not
reveal the same severe phenotype observed in the Csf1r-deﬁcient
animals (Yoshida et al., 1990). In fact, detailed examination of
Csf1op/op mice revealed the presence of microglia but at reduced
numbers (Blevins and Fedoroff, 1995). These ﬁndings clearly indi-
cated that survival and maintenance of microglia are majorly
inﬂuenced by Csf1r function. However, Csf1r may have Csf1-
independent functions in microglial homeostasis, suggesting the
existence of another ligand for this receptor. Indeed, (Lin et al.,
2008) discovered another ligand of the Csf1r known as IL-34. It
was shown that IL-34 and Csf1 share some similar signaling func-
tions via Csf1r and that both ligands can compensate for each
other (Wei et al., 2010). However, both ligands showed a differ-
ential expression pattern in vivo. Wang et al. (2012) generated
IL-34-deﬁcient animals with an insertion of the LacZ reporter
gene in the IL-34 gene locus, allowing its expression to be traced to
neurons. They showed that mostly microglia and Langerhans cells
of the epidermis are affected by the loss of IL-34. IL-34-deﬁcient
animals had reduced numbers of microglia and were consequently
more susceptible to viral infections in theCNS. Similar resultswere
recently obtained by Greter et al. (2012). They demonstrated that
IL-34 is expressed by speciﬁc neuronal subsets restricted to deﬁned
brain regions such as the cortex and hippocampus (Greter et al.,
2012). The authors found that microglial development was not
inﬂuenced by IL-34 deﬁciency. In contrast, microglial cell number
was decreased in speciﬁc regions of the adult brain. These results
indicated that IL-34 plays a role in the adult brain for microglial
survival and homeostasis. In another recent study, Erblich et al
(2011) analyzed microglia in Csf1op/op mice and Csf1r-deﬁcient
animals. They observed a reduced number of microglial cell in
the absence of Csf1, and a complete loss of microglia in Csf1r-
deﬁcient animals. These severe defects in microglial developments
resulted in disturbed brain development with a prominent pheno-
type of a thinned cortex. Additionally, a recent study showed that
the signaling of both IL-34 and Csf1 are important for microglial
proliferation upon neurodegeneration during prion infection and
AD (Gómez-Nicola et al., 2013). Injection of a blocking antibody
against Csf1r on activated microglia induced a strong reduction
of proliferating cells in both diseases. In turn, microglial prolif-
eration could be induced by administration of Csf1 and IL-34,
whereas IL-34 showed a stronger proliferative capacity then Csf1.
In addition to the studies from Wang et al. (2012) and Greter et al.
(2012), it was shown here that not only are neurons a source of
IL-34, astrocytes could also express this ligand under neurodegen-
erative conditions. Therefore, the sources of IL-34 might differ
depending on the cellular conditions and the time points of inves-
tigation. Interestingly, heterozygous mutations in the Csf1r locus
canbe found inpatientswithhereditary diffuse leukoencephalopa-
thy with spheroids, characterized by demyelination of the cerebral
white matter and formation of spheroids which lead to progressive
cognitive and motor dysfunction (Rademakers et al., 2012). How-
ever, it is still unclear, what roles IL-34 and Csf1 play in microglial
development or homeostasis in these patients. Future studies will
elucidate the detailed function of these important physiological
signaling molecules in microglia.
Release of nucleotides such as adenosine triphosphate (ATP) in
the CNS mimics an inﬂammatory insult in the parenchyma, espe-
cially after nerve injury, and could efﬁciently activate microglia
(Davalos et al., 2005). This activation is mediated by several
purinergic receptors on the microglial surface. Microglia are
equipped with a wide range of ionotropic (P2X4 and P2X7)
and metabotropic (P2Y1, P2Y2, and P2Y12) purinergic receptors
(Inoue, 2002; Haynes et al., 2006). Many studies focused on the
role of these nucleotides for microglial activation and showed an
important function in their early response to injury (Haynes et al.,
2006; Ohsawa et al., 2007; Ulmann et al., 2008). Nucleotides are
versatile effector molecules which initiate the fast recruitment of
microglia to injury sites for the release of neurotrophic factors
(Haynes et al., 2006; Ohsawa et al., 2007; Ulmann et al., 2008).
The purinergic receptors seem to be another subset of microglial
surface receptors which are important for the maintenance of
injured neurons and facilitating tissue homeostasis by microglia
(Inoue, 2002).
Therefore, it can be assumed that microglia are very important
for the development and maintenance of the neuronal network. As
soon as there is a microglial activation without any insult or infec-
tion that is solved, this activation can be disruptive and harmful
for developing and already existing neuronal networks.
ENDOGENOUS FACTORS REGULATING MICROGLIA
ACTIVATION
The state of the microglial cell is not only regulated by exogenous
signal via surface receptors. Their activation and maturation states
are tightly controlled by a subset of endogenous transcription fac-
tors. Factors like Runt-related transcription factor 1 (Runx1), ETS
(E-twenty six) family transcription factor Pu.1, and interferon
regulatory factor 8 (Irf8) are indispensable regulators of the differ-
entiation process during embryonic development (Ginhoux et al.,
2010; Kierdorf et al., 2013).
Runx1was already known for its crucial function during deﬁni-
tive hematopoiesis. Loss of Runx1 leads to a complete lack of HSC
development from the aortic endothelium, accompanied by an
abnormal fetal liver hematopoiesis (Okuda et al., 1996; North et al.,
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1999). Okuda et al. (1996) generated Runx1-deﬁcient animals and
showed that they die very early during embryonic development
at around 12.5 days post conception (dpc). Another study indi-
cated that Runx1-deﬁcient embryos also suffer from necrosis and
hemorrhages in the CNS (Wang et al., 1996). Cell tracing studies
in the early mouse embryo revealed that Runx1 is a transcription
factor which is already expressed in hematopoietic progenitors in
the extraembryonic blood islands (Samokhvalov et al., 2007). Gin-
houx et al. (2010) used an inducible Cre-recombinase under the
control of theRunx1promoter for their pulse labeling experiments
during early embryonic stages. Here, they targeted microglia by
pulse labeling Runx1+ progenitors in the yolk sac around 7.5
dpc, since Runx1 is expressed in early microglial progenitors. The
decisive role of Runx1 in myelopoiesis was recently described in
zebraﬁsh (Jin et al., 2012). Both transcription factors Pu.1 and
Runx1were shown to act in a negative feedback loop for the regula-
tion of Pu.1 expression levels and thereafter regulatingmyeloid cell
fate (Jin et al., 2012). These ﬁndings indicated a key role of Runx1
for myeloid and microglia development. However, it was unclear
at this point whether Runx1 is also involved in the cell homeostasis
of microglia. In a transcriptome analysis of laser-microdissected
microglia from the corpus callosum of rats, Runx1 was found
to be down regulated in ramiﬁed microglia of 4 week old rats,
compared to amoeboid microglia of 5 days old pubs (Parakalan
et al., 2012). Zusso et al. (2012) performed a detailed analysis for
the function of Runx1 in postnatal microglia. They showed that
Runx1 is not only a regulator of differentiation, but further reg-
ulates proliferation and homeostasis of postnatal microglia. They
further suggested that Runx1 might play an important function in
microglia by modulating the transition of amoeboid microglia to
ramiﬁed ones. Therefore, Runx1 is a non-redundant transcription
factor that is important for the activation and resting states of
microglia(Table 1).
The transcription factor Pu.1 is a master regulator of myeloid
development which is already required during the ﬁrst stages of
myeloid differentiation programs. Pu.1-deﬁcient animals indi-
cated a fundamental role of Pu.1 for myeloid and microglial
development (Scott et al., 1994; McKercher et al., 1996). These
animals died during the ﬁrst days after birth due to severe sep-
ticemia. Their lifespan could be extended by antibiotic treatment
or bone marrow transplantation (Beers et al., 2006). Mature B
cells and myeloid cells are completely missing in these mice.
Examination of several tissues revealed a complete loss of tis-
sue macrophages such as Kupffer cells, microglia, or other tissue
macrophages (Schulz et al., 2012). Another study demonstrated
that CNS cultures from Pu.1-deﬁcient animals showed reduced
proliferation of cortical precursors and reduced astrogliogene-
sis (Antony et al., 2011). Until now, there is no direct evidence
whether Pu.1 is also involved in the normal homeostasis of adult
microglia. However, several studies suggest a regulatory func-
tion in the microglia/macrophage activation state. Ponomarev
et al. (2011) down regulated Pu.1 in macrophages by overex-
pression of miRNA-124. The reduced levels of Pu.1 led to
deactivatedphenotypeof macrophages. Further studies areneeded
to verify the function of Pu.1 in activation and homeostasis of
microglia (Table 1).
Recent investigations on the development of microglia showed
that microglial development is tightly regulated by distinct tran-
scriptional programs. Schulz and colleagues deﬁned microglia as
myeloid cells that develop from a HSC-independent progenitor,
independent of the transcription factor c-myb, which, however,
is indispensable for the development of deﬁnitive HSCs (Mucen-
ski et al., 1991; Schulz et al., 2012). Microglia developed normally
in c-myb-deﬁcient animals, indicating that c-myb is not regulat-
ing microglial development (Table 1). Furthermore, they showed
that an induced ablation of c-myb in adult mice did not affect
Table 1 |Transcription factors regulating microglia development and homeostasis.
Transcription
factor
Microglia development Microglia homeostasis
c-myb → Independent of c-myb (Schulz et al., 2012; Kierdorf et al.,
2013)
→ After induced ablation of c-myb, no change in microglia cell
number (Schulz et al., 2012)
Runx-1 → Expressed on microglia progenitors in the yolk sac (Ginhoux
et al., 2010)
→Regulating proliferation and tissue homeostasis of postnatal
microglia (Zusso et al., 2012)
→Transition of amoeboid to ramiﬁedmorphology (Zusso et al.,
2012)
Pu.1 → Absence of microglia progenitors in the yolk sac; no
development of microglia (Scott et al., 1994; McKercher et al.,
1996; Beers et al., 2006; Schulz et al., 2012; Kierdorf et al., 2013)
→ No direct evidence yet for a functional role during microglia
cell homeostasis
Irf8 → Reduced number of microglia and microglial progenitors in
the yolk sac (Kierdorf et al., 2013)
→ Dysregulation of microglial cell morphology and function
(Horiuchi et al., 2012; Minten et al., 2012)
→ Defects in microglial activation (Masuda et al., 2012)
Hoxb8 → No direct evidence yet for a functional role during microglia
development
→ Mutant Hoxb8 microglia induce pathological grooming in
mice (Chen et al., 2010)
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adult microglia. C-myb could therefore be considered a tran-
scription factor that is redundant for microglia development and
homeostasis.
In a very recent study on microglial development, a detailed
characterization of microglial progenitors and factors which are
important for their development was performed (Kierdorf et al.,
2013). The transcriptional programing of microglial develop-
ment is tightly regulated by Pu.1 and the myeloid transcription
factor Irf8. Irf8 is a transcription factor which is known to be
important for the development of B cells and myeloid cells in
the bone marrow (Holtschke et al., 1996). It was shown that Irf8-
deﬁcient animals have a severe defect in the generation of mature
myeloid cells, ﬁnally resulting in chronic myelogenous leukemia
(CML)-like symptoms (Holtschke et al., 1996). Furthermore, Irf8-
deﬁcient animals were more susceptible to infections (Holtschke
et al., 1996). Mutations in the Irf8 locus have been found to result
in severe immunodeﬁciency in humans (Hambleton et al., 2011).
These patients had decreased mature DCs and monocytes in the
blood and suffered from recurrent bacterial infections after Bacil-
lus Calmette–Guérin (BCG) vaccination. The authors described
two mutations in the DNA-binding domain of Irf8 which were
shown to induce a reducedbinding to target genepromoter regions
like IL-12 and inducible nitric oxide synthetase (iNOS; Hamble-
ton et al., 2011). Additionally, Irf8 was found to be a susceptibility
gene for autoimmune diseases such as Lupus erythematodes and
MS (De Jager et al., 2009; The International Multiple Sclerosis
Genetics Consortium, 2011; Lessard et al., 2012).
Besides the detrimental role of Irf8 for microglial and myeloid
development, recent studies indicated a role of Irf8 in adult
microglia homeostasis and activation (Table 1). One report
demonstrated the involvement of Irf8 for the activation of
microglia during nerve injury (Masuda et al., 2012). A massive
upregulation of this transcription factor upon lesion induction
was detected. Irf8-deﬁcient animals showed less hypersensitiv-
ity after nerve injury, decreased activation marker levels in
microglia, and no changes inmicroglial proliferation. In this study,
no morphological abnormalities of Irf8-deﬁcient microglia were
described. In contrast, two recent studies showed that loss of Irf8
has severe effects on microglia already under physiological condi-
tions. Horiuchi et al. (2012) reported no changes in cell number
but found an abnormal cell morphology with reduced ramiﬁ-
cation and altered expression of ionized calcium-binding adapter
molecule (Iba)-1. The authors further described reducedmicroglia
proliferation in culture and diminished phagocytotic capacity in
the absence of Irf8. In addition, the authors investigated microglial
activation and detected an altered cytokine expression level similar
to Masuda et al. (2012). Another study found increased microglial
cell numbers and showed gross alterations in morphology and
surface area in the absence of Irf8 (Minten et al., 2012).
Another important transcription factor essential for microglial
homeostasis is Hoxb8. Hoxb8-deﬁcient animals showed exces-
sive grooming behavior (Greer and Capecchi, 2002). Chen et al.
(2010) were able to deﬁne Hoxb8 expression in the adult CNS
in regions associated with the grooming behavior in mice. In
humans, these brain areas correspond to the obsessive-compulsive
disorder (OCD) circuitry. OCD is a condition that is often charac-
terized by excessive behaviors dealing with cleanliness, including
grooming. Whereas the exact microglia-mediated mechanisms of
this pathological grooming were not identiﬁed in this study, the
authors could elucidate a role of Hoxb8 mutant microglia in a
behavioral disorder. Hoxb8 was found to be expressed only in
microglia in the CNS, but just in approximately 40% of the cell
population which should be derived from bone marrow cells as
the authors stated in this study. Loss of Hoxb8 led to a slightly
reduced microglial cell number, but no obvious change in cell
morphology. The authors showed that wild type bone marrow
transplantation in Hoxb8 mutants after total body irradiation res-
cued the pathological grooming behavior. The authors obtained
surprisingly high engraftment rates (up to 30%) of inﬁltrating
bone marrow-derived phagocytes (BMDPs) in the mutant CNS.
Furthermore, when they restricted the Hoxb8 deletion to the
hematopoietic system, they found the same pathological groom-
ing behavior and hair loss symptoms. This study is one of the
ﬁrst that shows that mutations and defects in microglia can result
in prominent behavioral syndromes in mice. Deciphering novel
functions of microglia for psychiatric disorders and behavioral
anomalies will open new avenues in neuroimmunology in the
future.
We conclude that microglia have different surface receptors
that are essential for microglial cell homeostasis by regulating
either survival and or activation properties. Dysregulation of these
receptors induce severe changes in the microglia, which could
potentially be harmful for neuronal networks, and result in devel-
opmental defects and/or neuropathological changes in the adult
CNS.
ACKNOWLEDGMENTS
We want to thank Tuan L. Tay for critical reading and editing.
Marco Prinz is supported by the DFG funded research unit (FOR)
1336, the BMBF-funded Competence Network of Multiple Scle-
rosis (KKNMS), the Competence Network of Neurodegenerative
Disorders (KNDD), and the DFG (PR 577/8-2).
REFERENCES
Alliot, F., Godin, I., and Pessac, B.
(1999). Microglia derive from pro-
genitors, originating from the yolk
sac, and which proliferate in the
brain. Brain Res. Dev. Brain Res. 117,
145–152.
Antony, J. M., Paquin, A., Nutt,
S. L., Kaplan, D. R., and
Miller, F. D. (2011). Endogenous
microglia regulate development
of embryonic cortical precursor
cells. J. Neurosci. Res. 89, 286–
298.
Bachstetter, A. D., Morganti, J. M., Jern-
berg, J., Schlunk, A., Mitchell, S.
H., Brewster, K. W., et al. (2011).
Fractalkine and CX3CR1 regulate
hippocampal neurogenesis in adult
and aged rats. Neurobiol. Aging 32,
2030–2044.
Barclay, A. N., Wright, G. J., Brooke,
G., and Brown, M. H. (2002). CD200
and membrane protein interactions
in the control of myeloid cells. Trends
Immunol. 23, 285–290.
Bazan, J. F., Bacon, K. B., Hardi-
man, G., Wang, W., Soo, K., Rossi,
D., et al. (1997). A new class of
membrane-bound chemokine
with a CX3C motif. Nature 385,
640–644.
Beers, D. R., Henkel, J. S., Xiao, Q.,
Zhao, W., Wang, J., Yen, A. A., et al.
(2006). Wild-type microglia extend
survival in PU.1 knockout mice with
familial amyotrophic lateral sclero-
sis. Proc. Natl. Acad. Sci. U.S.A. 103,
16021–16026.
Biber, K., Neumann, H., Inoue, K.,
and Boddeke, H. W. G. M. (2007).
Neuronal“On”and“Off”signals con-
trol microglia. Trends Neurosci. 30,
596–602.
Blevins, G., and Fedoroff, S. (1995).
Microglia in colony-stimulating fac-
tor 1-deﬁcient op/op mice. J. Neu-
rosci. Res. 40, 535–544.
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 44 | 6
“fncel-07-00044” — 2013/4/22 — 12:53 — page 7 — #7
Kierdorf and Prinz Microglia activation
Cardona, A. E., Pioro, E. P., Sasse, M.
E., Kostenko, V., Cardona, S. M.,
Dijkstra, I. M., et al. (2006). Con-
trol of microglial neurotoxicity by the
fractalkine receptor. Nat. Neurosci. 9,
917–924.
Cecchini, M. G., Dominguez, M. G.,
Mocci, S., Wetterwald, A., Felix, R.,
Fleisch, H., et al. (1994). Role of
colony stimulating factor-1 in the
establishment and regulation of tis-
sue macrophages during postnatal
development of the mouse. Develop-
ment 120, 1357–1372.
Chen, S. -K., Tvrdik, P., Peden, E.,
Cho, S., Wu, S., Spangrude, G.,
et al. (2010). Hematopoietic origin
of pathological grooming in Hoxb8
mutant mice. Cell 141, 775–785.
Chitu, V., and Stanley, E. R.
(2006). Colony-stimulating factor-
1 in immunity and inﬂammation.
Curr. Opin. Immunol. 18, 39–48.
Colonna, M. (2003). TREMs in the
immune system and beyond. Nat.
Rev. Immunol. 3, 445–453.
Cuadros, M. A., and Navascués, J.
(1998). The origin and differen-
tiation of microglial cells during
development. Prog. Neurobiol. 56,
173–189.
Dai, X.-M., Ryan, G. R., Hapel, A.
J., Dominguez, M. G., Russell, R.
G., Kapp, S., et al. (2002). Targeted
disruption of the mouse colony-
stimulating factor 1 receptor gene
results in osteopetrosis, mononu-
clear phagocyte deﬁciency, increased
primitive progenitor cell frequencies,
and reproductive defects. Blood 99,
111–120.
Davalos, D., Grutzendler, J., Yang,
G., Kim, J. V., Zuo, Y., Jung, S.,
et al. (2005). ATP mediates rapid
microglial response to local brain
injury in vivo. Nat. Neurosci. 8,
752–758.
De Jager, P. L., Jia, X., Wang, J., de
Bakker, P. I. W., Ottoboni, L., Aggar-
wal, N. T., et al. (2009). Meta-analysis
of genome scans and replication
identifyCD6, IRF8 andTNFRSF1Aas
new multiple sclerosis susceptibility
loci. Nat. Genet. 41, 776–782.
del Rio-Hortega, P. (1919). El “tercer
elemento” de los centros nerviosus.
I. La microglia en estado normal.
II. Intervencion de la microglia en
los procesos patologicos (Celulas en
bastoncito y cuerpos granuloadi-
posos). III. Naturaleza probable de la
microglia. Bol. R. Soc. Esp. Hist. Nat.
Secc. Biol. 9, 68–120.
del Rio-Hortega, P. (1932). “Microglia,”
in Cytology and Cellular Pathology
of the Nervous System, ed. W. Pen-
ﬁeld (New York: P. B. Hoeber),
483–534.
Erblich, B., Zhu, L., Etgen, A.
M., Dobrenis, K., and Pollard,
J. W. (2011). Absence of colony
stimulation factor-1 receptor results
in loss of microglia, disrupted
brain development and olfactory
deﬁcits. PLoS ONE 6:e26317. doi:
10.1371/journal.pone.0026317
Fuhrmann, M., Bittner, T., Jung, C. K.
E., Burgold, S., Page, R. M., Mit-
teregger, G., et al. (2010). Microglial
Cx3cr1 knockout prevents neuron
loss in a mouse model of Alzheimer’s
disease. Nat. Neurosci. 13,
411–413.
Ginhoux, F., Greter, M., Leboeuf, M.,
Nandi, S., See, P., Gokhan, S.,
et al. (2010). Fate mapping analy-
sis reveals that adult microglia derive
from primitive macrophages. Science
330, 841–845.
Gómez-Nicola, D., Fransen,N. L., Suzzi,
S., and Perry, V. H. (2013). Reg-
ulation of microglial proliferation
during chronic neurodegeneration. J.
Neurosci. 33, 2481–2493.
Greer, J.M., andCapecchi,M. R. (2002).
Hoxb8 is required for normal groom-
ing behavior in mice. Neuron 33,
23–34.
Greter, M., Lelios, I., Pelczar, P., Hoeffel,
G., Price, J., Leboeuf,M., et al. (2012).
Stroma-derived interleukin-34 con-
trols the development and mainte-
nance of langerhans cells and the
maintenance of microglia. Immunity
37, 1050–1060.
Hambleton, S., Salem, S., Bustamante,
J., Bigley, V., Boisson-Dupuis, S.,
Azevedo, J., et al. (2011). IRF8
mutations and human dendritic-cell
immunodeﬁciency. N. Engl. J. Med.
365, 127–138.
Hanisch, U.-K., and Kettenmann, H.
(2007). Microglia: active sensor and
versatile effector cells in the normal
and pathologic brain. Nat. Neurosci.
10, 1387–1394.
Harrison, J. K., Jiang, Y., Chen, S.,
Xia, Y., Maciejewski, D., McNamara,
R. K., et al. (1998). Role for neu-
ronally derived fractalkine in medi-
ating interactions between neurons
and CX3CR1-expressing microglia.
Proc. Natl. Acad. Sci. U.S.A. 95,
10896–10901.
Haynes, S. E., Hollopeter, G., Yang, G.,
Kurpius,D.,Dailey,M.E.,Gan,W.-B.,
et al. (2006). The P2Y12 receptor reg-
ulates microglial activation by extra-
cellular nucleotides. Nat. Neurosci. 9,
1512–1519.
Hoek, R. M., Ruuls, S. R.,Murphy, C. A.,
Wright, G. J., Goddard, R., Zurawski,
S. M., et al. (2000). Down-regulation
of the macrophage lineage through
interaction with OX2 (CD200). Sci-
ence 290, 1768–1771.
Holtschke, T., Löhler, J., Kanno, Y.,
Fehr, T., Giese, N., Rosenbauer, F.,
et al. (1996). Immunodeﬁciency and
chronic myelogenous leukemia-like
syndrome in mice with a targeted
mutation of the ICSBP gene. Cell 87,
307–317.
Horiuchi, M., Wakayama, K., Itoh,
A., Kawai, K., Pleasure, D.,
Ozato, K., et al. (2012). Inter-
feron regulatory factor 8/interferon
consensus sequence binding pro-
tein is a critical transcription fac-
tor for the physiological phenotype
of microglia. J. Neuroinﬂammation
9, 227.
Hoshiko, M., Arnoux, I., Avignone,
E., Yamamoto, N., and Audinat, E.
(2012). Deﬁciency of the microglial
receptor CX3CR1 impairs postnatal
functional development of thalamo-
cortical synapses in the barrel cortex.
J. Neurosci. 32, 15106–15111.
Hua, J.Y., and Smith, S. J. (2004). Neural
activity and the dynamics of central
nervous system development. Nat.
Neurosci. 7, 327–332.
Hughes, P. M., Botham, M. S., Frentzel,
S., Mir, A., and Perry, V. H. (2002).
Expression of fractalkine (CX3CL1)
and its receptor, CX3CR1, dur-
ing acute and chronic inﬂamma-
tion in the rodent CNS. Glia 37,
314–327.
Inoue, K. (2002). Microglial activation
by purines and pyrimidines. Glia 40,
156–163.
Jin, H., Li, L., Xu, J., Zhen, F., Zhu, L.,
Liu, P. P., et al. (2012). Runx1 regu-
lates embryonic myeloid fate choice
in zebraﬁsh through a negative feed-
back loop inhibiting Pu.1 expression.
Blood 119, 5239–5249.
Jung, S., Aliberti, J., Graemmel, P.,
Sunshine, M. J., Kreutzberg, G.
W., Sher, A., et al. (2000). Analy-
sis of fractalkine receptor CX3CR1
function by targeted deletion and
green ﬂuorescent protein reporter
gene insertion. Mol. Cell. Biol. 20,
4106–4114.
Kaur, C., Hao,A. J.,Wu, C. H., and Ling,
E. A. (2001). Origin of microglia.
Microsc. Res. Tech. 54, 2–9.
Kierdorf, K., Erny, D., Goldmann, T.,
Sander, V., Schulz, C., Perdiguero, E.
G., et al. (2013). Microglia emerge
from erythromyeloid precursors via
Pu.1- and Irf8-dependent pathways.
Nat. Neurosci. 16, 273–280.
Kim, K.-W., Vallon-Eberhard, A., Zig-
mond, E., Farache, J., Shezen,
E., Shakhar, G., et al. (2011). In
vivo structure/function and expres-
sion analysis of the CX3C chemokine
fractalkine. Blood 118, e156–e167.
Klünemann, H. H., Ridha, B. H., Magy,
L., Wherrett, J. R., Hemelsoet, D. M.,
Keen, R. W., et al. (2005). The genetic
causes of basal ganglia calciﬁcation,
dementia, and bone cysts: DAP12 and
TREM2. Neurology 64, 1502–1507.
Lawson, L. J., Perry, V. H., Dri, P., and
Gordon, S. (1990). Heterogeneity in
the distribution and morphology of
microglia in the normal adult mouse
brain. Neuroscience 39, 151–170.
Lee, S., Varvel, N. H., Konerth, M. E.,
Xu, G., Cardona, A. E., Ransohoff,
R. M., et al. (2010). CX3CR1 deﬁ-
ciency altersmicroglial activation and
reduces beta-amyloid deposition in
two Alzheimer’s disease mouse mod-
els. Am. J. Pathol. 177, 2549–2562.
Lessard, C. J., Adrianto, I., Ice, J. A.,
Wiley, G. B., Kelly, J. A., Glenn, S. B.,
et al. (2012). Identiﬁcation of IRF8,
TMEM39A, and IKZF3-ZPBP2 as
susceptibility loci for systemic lupus
erythematosus in a large-scale mul-
tiracial replication study. Am. J. Hum.
Genet. 90, 648–660.
Lin, H., Lee, E., Hestir, K., Leo, C.,
Huang, M., Bosch, E., et al. (2008).
Discovery of a cytokine and its recep-
tor by functional screening of the
extracellular proteome. Science 320,
807–811.
Linnartz, B., and Neumann, H. (2012).
Microglial activatory (immunore-
ceptor tyrosine-based activation
motif)- and inhibitory (immunore-
ceptor tyrosine-based inhibition
motif)-signaling receptors for recog-
nition of the neuronal glycocalyx.
Glia 61, 37–46.
Liu, Z., Condello, C., Schain, A.,
Harb, R., and Grutzendler, J. (2010).
CX3CR1 in microglia regulates brain
amyloid deposition through selective
protoﬁbrillar amyloid-β phagocyto-
sis. J. Neurosci. 30, 17091–17101.
Masuda, T., Tsuda, M., Yoshinaga, R.,
Tozaki-Saitoh, H., Ozato, K., Tamura,
T., et al. (2012). IRF8 is a critical
transcription factor for transforming
microglia into a reactive phenotype.
Cell Rep. 1, 334–340.
McKercher, S. R., Torbett, B. E., Ander-
son, K. L., Henkel, G. W., Vestal, D.
J., Baribault, H., et al. (1996). Tar-
geted disruption of the PU.1 gene
results in multiple hematopoietic
abnormalities. EMBO J. 15, 5647–
5658.
Minten, C., Terry, R., Deffrasnes, C.,
King, N. J. C., and Campbell, I. L.
(2012). IFN regulatory factor 8 is a
key constitutive determinant of the
morphological and molecular prop-
erties of microglia in the CNS. PLoS
ONE 7:e49851. doi: 10.1371/jour-
nal.pone.0049851
Mucenski, M. L., McLain, K., Kier,
A. B., Swerdlow, S. H., Schreiner,
C. M., Miller, T. A., et al. (1991).
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 44 | 7
“fncel-07-00044” — 2013/4/22 — 12:53 — page 8 — #8
Kierdorf and Prinz Microglia activation
A functional c-myb gene is required
for normal murine fetal hepatic
hematopoiesis. Cell 65, 677–689.
Neumann, H., and Takahashi, K.
(2007). Essential role of the
microglial triggering receptor expre-
ssed on myeloid cells-2 (TREM2)
for central nervous tissue immune
homeostasis. J. Neuroimmunol. 184,
92–99.
Nimmerjahn, A., Kirchhoff, F., and
Helmchen, F. (2005). Resting
microglial cells are highly dynamic
surveillants of brain parenchyma in
vivo. Science 308, 1314–1318.
North, T., Gu, T. L., Stacy, T., Wang,
Q., Howard, L., Binder, M., et al.
(1999). Cbfa2 is required for the for-
mation of intra-aortic hematopoietic
clusters. Development 126, 2563–
2575.
Ohsawa, K., Irino, Y., Nakamura,
Y., Akazawa, C., Inoue, K., and
Kohsaka, S. (2007). Involvement of
P2X4 and P2Y12 receptors in ATP-
induced microglial chemotaxis. Glia
55, 604–616.
Okuda, T., van Deursen, J., Hiebert,
S. W., Grosveld, G., and Down-
ing, J. R. (1996). AML1, the target
of multiple chromosomal transloca-
tions in human leukemia, is essential
for normal fetal liver hematopoiesis.
Cell 84, 321–330.
Paloneva, J., Autti, T., Raininko, R.,
Partanen, J., Salonen, O., Puranen,
M., et al. (2001). CNS manifestations
of Nasu–Hakola disease: a frontal
dementia with bone cysts. Neurology
56, 1552–1558.
Pan, Y., Lloyd, C., Zhou, H., Dolich,
S., Deeds, J., Gonzalo, J.-A., et al.
(1997). Neurotactin, a membrane-
anchored chemokine upregulated in
brain inﬂammation. Nature 387,
611–617.
Paolicelli, R. C., Bolasco, G., Pagani, F.,
Maggi, L., Scianni, M., Panzanelli,
P., et al. (2011). Synaptic pruning
by microglia is necessary for nor-
mal brain development. Science 333,
1456–1458.
Parakalan, R., Jiang, B., Nimmi, B.,
Janani, M., Jayapal, M., Lu, J.,
et al. (2012). Transcriptome analysis
of amoeboid and ramiﬁed microglia
isolated from the corpus callosum of
rat brain. BMC Neurosci. 13:64. doi:
10.1186/1471-2202-13-64
Ponomarev, E. D., Veremeyko, T.,
Barteneva, N., Krichevsky, A. M., and
Weiner, H. L. (2011). MicroRNA-
124 promotes microglia quiescence
and suppresses EAE by deactivat-
ing macrophages via the C/EBP-
α-PU.1 pathway. Nat. Med. 17,
64–70.
Prinz, M., and Priller, J. (2010). Tick-
ets to the brain: role of CCR2
and CX3CR1 in myeloid cell entry
in the CNS. J. Neuroimmunol. 224,
80–84.
Prinz, M., Priller, J., Sisodia, S.
S., and Ransohoff, R. M. (2011).
Heterogeneity of CNS myeloid cells
and their roles in neurodegeneration.
Nat. Neurosci. 14, 1227–1235.
Rademakers, R., Baker, M., Nichol-
son, A. M., Rutherford, N. J., Finch,
N., Soto-Ortolaza, A., et al. (2012).
Mutations in the colony stimulating
factor 1 receptor (CSF1R) gene cause
hereditary diffuse leukoencephalopa-
thy with spheroids. Nat. Genet. 44,
200–205.
Ransohoff, R. M., and Perry, V.
H. (2009). Microglial physio-
logy: unique stimuli, specialized
responses. Annu. Rev. Immunol. 27,
119–145.
Rogers, J. T., Morganti, J. M., Bach-
stetter, A. D., Hudson, C. E., Peters,
M. M., Grimmig, B. A., et al.
(2011). CX3CR1 deﬁciency leads to
impairment of hippocampal cogni-
tive function and synaptic plasticity.
J. Neurosci. 31, 16241–16250.
Saijo, K., and Glass, C. K. (2011).
Microglial cell origin and pheno-
types in health and disease. Nat. Rev.
Immunol. 11, 775–787.
Samokhvalov, I. M., Samokhvalova, N.
I., andNishikawa, S. (2007). Cell trac-
ing shows the contributionof the yolk
sac to adult haematopoiesis. Nature
446, 1056–1061.
Schulz, C., Perdiguero, E. G., Chorro,
L., Szabo-Rogers, H., Cagnard, N.,
Kierdorf, K., et al. (2012). A lineage
of myeloid cells independent of Myb
and hematopoietic stem cells. Science
336, 86–90.
Scott, E. W., Simon, M. C., Anastasi,
J., and Singh, H. (1994). Require-
ment of transcription factor PU.1 in
the development of multiple hemato-
poietic lineages. Science 265, 1573–
1577.
Takahashi, K., Prinz, M., Stagi, M.,
Chechneva, O., and Neumann, H.
(2007). TREM2-transduced myeloid
precursors mediate nervous tissue
debris clearance and facilitate recov-
ery in an animal model of multiple
sclerosis. PLoS Med. 4:e124. doi:
10.1371/journal.pmed.0040124
The International Multiple Sclerosis
Genetics Consortium. (2011). The
genetic association of variants in
CD6, TNFRSF1A and IRF8 to mul-
tiple sclerosis: a multicenter case–
control study. PLoS ONE 6:e18813.
doi: 10.1371/journal.pone.0018813
Ulmann, L., Hatcher, J. P., Hughes, J.
P., Chaumont, S., Green, P. J., Con-
quet, F., et al. (2008). Up-regulation
of P2X4 receptors in spinal microglia
after peripheral nerve injury medi-
ates BDNF release and neuropathic
pain. J. Neurosci. 28, 11263–
11268.
van Beek, E. M., Cochrane, F., Bar-
clay, A. N., and van den Berg, T. K.
(2005). Signal regulatory proteins in
the immune system. J. Immunol. 175,
7781–7787.
Wang, Q., Stacy, T., Binder, M., Marin-
Padilla, M., Sharpe, A. H., and Speck,
N. A. (1996). Disruption of the Cbfa2
gene causes necrosis and hemorrhag-
ing in the central nervous system and
blocks deﬁnitive hematopoiesis. Proc.
Natl. Acad. Sci. U.S.A. 93, 3444–
3449.
Wang, Y., Szretter, K. J., Vermi, W., Gil-
ﬁllan, S., Rossini, C., Cella, M., et al.
(2012). IL-34 is a tissue-restricted
ligand of CSF1R required for the
development of Langerhans cells
and microglia. Nat. Immunol. 13,
753–760.
Wei, S., Nandi, S., Chitu, V., Yeung, Y.-
G., Yu, W., Huang, M., et al. (2010).
Functional overlap but differential
expression of CSF-1 and IL-34 in
their CSF-1 receptor-mediated regu-
lation of myeloid cells. J. Leukoc. Biol.
88, 495–505.
Yoshida, H., Hayashi, S., Kunisada,
T., Ogawa, M., Nishikawa, S., Oka-
mura, H., et al. (1990). The murine
mutation osteopetrosis is in the cod-
ing region of the macrophage colony
stimulating factor gene. Nature 345,
442–444.
Zusso, M., Methot, L., Lo, R., Green-
halgh, A. D., David, S., and Stifani, S.
(2012). Regulation of postnatal fore-
brain amoeboidmicroglial cell prolif-
eration and development by the tran-
scription factor runx1. J. Neurosci. 32,
11285–11298.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 03 February 2013; paper
pending published: 15 February 2013;
accepted: 30 March 2013; published
online: 23 April 2013.
Citation: Kierdorf K and Prinz M
(2013) Factors regulating microglia acti-
vation. Front. Cell. Neurosci. 7:44. doi:
10.3389/fncel.2013.00044
Copyright © 2013 Kierdorf and Prinz.
This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 44 | 8
